12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies

183 Pages·2010·11.73 MB·English

Acknowledgements

Program Committee for Scientific Input

NCI Office of Communications and

Education for cover art

and

National Institute of Dental and Craniofacial

Research for financial support

OFFICE OF CONTINUING EDUCATION IN THE HEALTH PROFESSIONS

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the
Accreditation Council for Continuing Medical Education through the joint sponsorship of The George Washington
University Medical Center and the National Institutes of Health. The George Washington University Medical Center
is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement
The George Washington University Medical Center designates this educational activity for a maximum of 5 AMA PRA
Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the
activity.

Policy on Speaker and Provider Disclosure
The George Washington University Medical Center has a disclosure policy whereby everyone in a position to control
the content of an educational activity must disclose all relevant financial relationships with commercial interests. In
addition, speakers must also disclose any unlabled/unapproved uses of drugs or devices that they plan to discuss in
their presentation(s). Individuals who fail to disclose potential conflicts of interest are disqualified from participation
in planning or implementing this CME activity. Potential conflicts of interest are resolved and documented. Detailed
disclosure will be made in the activity handout materials.

Learning Objectives
At the end of this activity, attendees should be able to:

1. Propose trends of specific malignancies that may occur in the context of HIV infection (AIDS defining and non-
AIDS defining) and other acquired immunodeficiencies, and identify cofactors (ie. environmental, viral, and
behavioral) that may be associated with the development of these malignancies, if known. Describe which
populations (geographic, ethnic, racial, sex, age, etc.) may be predisposed to developing specific malignancies.

2. Describe how the use of state-of-the-science information in the epidemiology, pathogenesis, and clinical aspects
of malignancies in HIV positive and other immunocompromised patients can lead to more effective prevention,
diagnosis and treatment in those that are susceptible to these malignancies.

3. Describe how chronic immunosuppression (either in transplant recipients or HIV positive individuals on HAART)
impacts the incidence and types of cancer, and the choice of therapies in those patients who develop
malignancies.

ROSS HALL, SUITE 313-D • 2300 EYE STREET, NW • WASHINGTON, DC 20037• 202-994-4285 • TOLL FREE: 800-314-1423 •
FAX: [phone]

WEB: www.gwumc.edu/cehp

12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies
Lister Hill Auditorium, NIH, Bethesda, Maryland
April 26-27, 2010

PROGRAM CO-CHAIRS*
Alexandra M. Levine, MD, MACP
Robert Yarchoan, MD Dr. Levine disclosed a consulting
Dr. Yarchoan disclosed that he has a relationship with Genentech and a speakers
Material Transfer Agreement with Johnson bureau relationship with Abbott Laboratories
and Johnson
Richard Little, MD
Geraldina Dominguez, PhD Nothing to disclose
Nothing to disclose
Douglas Lowy, MD
PROGRAM COMMITTEE* Dr. Lowy disclosed that he receives
royalties via the NIH for an invention that
Richard F. Ambinder, MD, PhD the NIH licenses to Merck and
Nothing to disclose GlaxoSmithKline

Leona Ayers, MD Sam Mbulaiteye, MD
Nothing to disclose Nothing to disclose

Kishor Bhatia, PhD, FRCPath Mostafa Nokta, MD, PhD
Nothing to disclose Nothing to disclose

John T. Brooks, MD Joel Palefsky, MD, FRCP(C)

Nothing to disclose Dr. Palefsky disclosed that he is a

consultant, advisory committee member,

Corey Casper, MD, MPH and independent contractor with Merck.

Nothing to disclose
C. David Pauza, PhD
Ethel Cesarman, MD, PhD Nothing to disclose
Nothing to disclose
Elizabeth Read-Connole, PhD
Dirk Dittmer, PhD Nothing to disclose
Nothing to disclose
Isaac R. Rodriguez-Chavez, PhD, MS, MHS
Robert W. Eisinger, PhD Nothing to disclose
Nothing to disclose
Sylvia Silver, DA
Eric A. Engels, MD, MPH Nothing to disclose
Nothing to disclose
Michael J. Silverberg, PhD, MPH
Joe Harford, PhD Dr. Silverberg disclosed that he is an
Nothing to disclose independent contractor with Pfizer and
Merck.
Rebecca Liddell Huppi, PhD
Nothing to disclose Joseph Sparano, MD
Nothing to disclose
Elliott D. Kieff, MD, PhD
Nothing to disclose
*The program chairs and committee were tasked with identifying program content and speakers. The course director
conducted the meeting with the best interest of the learning needs in mind. Both chairs and all committee members
completed disclosure documents. Any potential conflicts that arose were mitigated by either 1) self-recusal, or 2)
concurrence by the committee that the content identified was scientifically sound and without bias and that the
speakers identified would deliver balanced scientific presentations on raw data and sound evidence and make no
commercial recommendations. It has been determined that no conflicts of interest exist in this role.
12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies

Lister Hill Auditorium, NIH, Bethesda, Maryland

April 26-27, 2010

Denise Whitby, PhD Frank Ruscetti, Ph.D.
Nothing to disclose Nothing to disclose

T-C Wu, MD, PhD Rengaswamy Sankaranarayanan, M.D
Nothing to disclose Nothing to disclose

Accredited Faculty

Christopher Buck, Ph.D.
Nothing to disclose

Don Ganem, M.D.
Dr Ganem disclosed a consulting
relationship with 3V, Kearny Venture
Partners and Novartis. After a review of his
presentation it was determined that he will
discuss raw data only and make no
recommendations.

Clifford Gary Ph.D.
Nothing to disclose

Aisha O. Jumaan, Ph.D., M.P.H.
Nothing to disclose

Ari Melnick, M.D
Nothing to disclose

Eugene Mutimura, Ph.D.
Dr. Mutimura will discuss CareHPV which is
under development and for investigational
use only. He has no financial relationships
to disclose

Robert Newton, M.B.B.S., D.Phil., FFPH
Nothing to disclose

Joel Palefsky, M.D., FRCP(C)
Dr. Palefsky disclosed that he is a
consultant, advisory committee member,
and independent contractor with Merck.
After a review of his presentation it was
determined that he will discuss raw data
only and make no recommendations.

Groesbeck P. Parham, M.D
Nothing to disclose
*The program chairs and committee were tasked with identifying program content and speakers. The course director
conducted the meeting with the best interest of the learning needs in mind. Both chairs and all committee members
completed disclosure documents. Any potential conflicts that arose were mitigated by either 1) self-recusal, or 2)
concurrence by the committee that the content identified was scientifically sound and without bias and that the
speakers identified would deliver balanced scientific presentations on raw data and sound evidence and make no
commercial recommendations. It has been determined that no conflicts of interest exist in this role.